HOUSE_OVERSIGHT_024055.jpg
2.01 MB
Extraction Summary
1
People
3
Organizations
0
Locations
0
Events
1
Relationships
3
Quotes
Document Information
Type:
Investment memorandum / fund prospectus
File Size:
2.01 MB
Summary
This document appears to be a page from an investment memorandum for 'NLV-III' (New Leaf Ventures III). It outlines the 'New Leaf' team's due diligence process, risk assessment factors (such as IP strength and regulatory risks), and team-oriented management philosophy. It also details the intended portfolio composition, targeting 24-28 companies with a specific asset allocation focused heavily on biopharmaceuticals (50-60%).
People (1)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Management |
Group responsible for investment philosophy, deal sourcing, and portfolio management for New Leaf/NLV-III.
|
Organizations (3)
| Name | Type | Context |
|---|---|---|
| New Leaf |
Investment firm described in the document.
|
|
| NLV-III |
Specific fund mentioned regarding targeted sectors (New Leaf Ventures III).
|
|
| House Oversight Committee |
Indicated by the Bates stamp 'HOUSE_OVERSIGHT_024055'.
|
Key Quotes (3)
"New Leaf seeks to avoid “lone ranger” behavior and instead actively implements a team approach."Source
HOUSE_OVERSIGHT_024055.jpg
Quote #1
"The targeted portfolio is expected to be diversified across biopharmaceuticals (50 - 60%), information convergence (up to 25%), and the remainder across investments in later stage medical device and biological tools and infrastructure companies."Source
HOUSE_OVERSIGHT_024055.jpg
Quote #2
"Investments will include both development stage and start-up stage companies, as well as growth equity or expansion capital investment in NLV-III’s targeted sectors..."Source
HOUSE_OVERSIGHT_024055.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document